Journal of the National Comprehensive Cancer Network

Papers
(The H4-Index of Journal of the National Comprehensive Cancer Network is 53. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
NCCN News1135
Intravenous Patient-Controlled Analgesia Versus Oral Opioid to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase II Trial975
CLO22-069: Radiation Induced Lymphopenia (RAILs on Time Saves Nine!) In Carcinoma Esophagus!705
Relapsed/Refractory CLL/SLL: Overcoming Resistance to Covalent BTKi and/or BCL2 Inhibitors536
HSR22-171: Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Older Versus Younger Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in a Pha468
NCCN News383
PCL22-186: A Potential Biomarker for Radiosensitivity of Squamous Cell Carcinomas in the Head and Neck359
HSR22-154: Treatment Patterns Following Osimertinib Discontinuation in Patients With EGFR Mutated Metastatic NSCLC346
HSR24-169: Autonomic Symptoms May Suggest Paraneoplastic Neurological Syndromes in Small Cell Lung Cancer334
HSR24-153: Real-World Clinical Outcomes of First-Line Therapies and Treatment Regimens for BRAF-Mutant Advanced/Metastatic Melanoma: Retrospective Observational Study322
CRE24-049: Extrapulmonary Small Cell Carcinoma of Gallbladder Presenting as Acute Cholecystitis315
HSR24-127: Rectal Cancer Disparities in Age and Overall Survival Among American Indian and Alaska Native Vs Non-Hispanic White Populations311
Highlights of the NCCN Oncology Research Program295
CLO24-055: Outcomes With Sacituzumab Govitecan in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis295
My Report Card284
EHR-Integrated Patient-Reported Outcomes in Ambulatory Oncology: A Critical Opportunity for Timely and Targeted Palliative Care284
Localized Gastroesophageal Cancers: Can We Shift the Current Treatment Paradigms?244
CLO23-035: Expression of PD-L1 Through Evolution Phase From Pre-Invasive to Invasive Lung Adenocarcinoma222
HSR23-103: Pancreatic Cancer: The Impact of Early Connectivity and Coordination of Care on Retention and Time to Treat209
CLO23-045: A Prospective Interventional Study to Assess the Response of Systemic Chemotherapy in Aggressive, Recurrent Giant Cell Tumor203
CLO23-043: Optimal Interval Between Immune Therapy and Targeted Therapy With Sotorasib in Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer168
CLO22-052: A Tale of Two Schedules: A Study of the Efficacy and Toxicity Outcomes of Extended Durvalumab Dosing in Patients with Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)148
EPR24-113: The Role of Social Determinants of Health in Gastrointestinal Cancer Outcomes in the United States Context: A Systematic Review146
HSR24-163: Comparative Assessment of Social Determinants of Health in Community and Academic Hospitals for Patients Diagnosed With Hepatocellular Carcinoma140
Oncology Survivorship Care Clinics: Design and Implementation of Survivorship Care Delivery Systems at NCCN Member Institutions131
BPI25-005: Molecular Biomarker Testing Patterns and Turn-Around Time in US Patients With Advanced Non-Small Cell Lung Cancer127
BPI25-019: Empirical Study to Estimate Real World Impact of Delay in EGFR Testing on Healthcare Resource Utilization and Cost Burden Among Early-Stage NSCLC Patients124
BIO25-027: Addressing Early Diagnosis Challenges: Utilizing C the Signs Clinical Decision Support Platform for Pancreatic Cancer Risk Assessment118
Highlights of the NCCN Oncology Research Program116
Highlights of the NCCN Oncology Research Program111
A New Administration and JNCCN106
NCCN News102
Statin Use During Concurrent Chemoradiotherapy for Advanced Nasopharyngeal Cancer101
EPR24-099: Clinical and Epidemiological Characterization of the Oncologic Population in a Third Level Hospital in Northeastern Mexico98
HSR24-152: Patient-Reported Outcome (PRO) Data in Oncology NDAs Approved by the FDA (2018–2021): A Review of Criticism and Concerns in Comments From Regulators98
CLO24-060: Organomegalies as a Predictive Indicator of Leukemia Cutis in the Patients With Acute Myeloid Leukemia90
YIA24-005: MAIT Cells are Reduced in Anorectal Mucosal Melanomas Compared to Cutaneous Melanoma GI Metastases90
Patient-Reported Symptom Complexity and Acute Care Utilization Among Patients With Cancer: A Population-Based Study Using a Novel Symptom Complexity Algorithm and Observational Data83
HSR25-181: Assessment of Content Validity of the Functional Assessment of Cancer Therapy – Cutaneous T-Cell Lymphoma (FACT-CTCL)81
HSR25-141: Adolescent and Young Adult Cancer Patients: Our Most Financially Vulnerable Demographic79
CLO25-078: Deciphering Risk of Early Biochemical Recurrence in Prostate Cancer Prior to Definitive Therapy78
EPR25-128: Epidemiology of Olfactory Neuroblastoma: A SEER Stat Review76
Evaluation of NCI-Designated Cancer Center and Comprehensive Cancer Center Survivorship-Focused Websites: Information Provided and Accessibility66
Highlights of the NCCN Oncology Research Program63
Empowering Care Teams: Redefining Message Management to Enhance Care Delivery and Alleviate Oncologist Burnout63
Advances in the Treatment of Recurrent Ovarian Cancer and Rare Malignant Ovarian Germ Cell Tumors63
Association of Polypharmacy and Potentially Inappropriate Medications With Frailty Among Older Adults With Blood Cancers61
EPR25-138: Glioblastoma Multiforme: A SEER STAT Analysis of Epidemiological, Laterality, and Anatomical Prognostic Indicators60
Hemithyroidectomy Versus Total Thyroidectomy for Sporadic Medullary Thyroid Cancer: A Chinese Nationwide Large-Scale Cohort Study59
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.202158
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.202257
Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology56
Proportion of Gleason Score ≥8 Prostate Cancer on Biopsy and Tumor Aggressiveness in Matched Cohorts of East Asian and Non-East Asian Men55
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.202553
0.15600895881653